title: Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab.
authors.affiliation: Duke University School of Medicine, Durham, North Carolina.
authors.forename: Ashwin
authors.initials: A
authors.lastname: Agarwal
authors.affiliation: Department of Pathology, Duke University School of Medicine, Durham, North Carolina.
authors.forename: Willis
authors.initials: W
authors.lastname: Barrow
authors.affiliation: Department of Pathology, Duke University School of Medicine, Durham, North Carolina.
authors.forename: M Angelica
authors.initials: MA
authors.lastname: Selim
authors.affiliation: Department of Dermatology, Duke University School of Medicine, Durham, North Carolina.
authors.forename: Matilda W
authors.initials: MW
authors.lastname: Nicholas
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001707:Biopsy, Needle; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D040521:Subcutaneous Tissue / Q000473:pathology*; D016463:Sweet Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab